Edmund Fiksinski, MD
Interventional Cardiology · Omaha, NENPI 1124079819
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 245 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by Abbott at 25.1% of the total. That places this record below the midpoint for interventional cardiology clinicians in NE, where the typical reported total is $6,648.
Across 245 payments — averaging $27.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Boston Scientific$1K
- Novartis$861
- Abiomed$430
- Medtronic$409
- Amgen$282
- plus $2K from 29 others
Across 12 payments — averaging $1344.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$16K
What the payments were for
- Food & beverage$6,648100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 16 | $1,669 |
| Boston Scientific | 43 | $1,289 |
| Novartis | 58 | $861 |
| Abiomed | 5 | $430 |
| Medtronic(2 entities) | 12 | $409 |
| Amgen | 19 | $282 |
| Sanofi-aventis U.S. LLC | 19 | $274 |
| Johnson & Johnson | 12 | $165 |
| Heartflow, Inc. | 2 | $157 |
| Bridgebio Pharma, Inc. | 5 | $151 |
| Boehringer Ingelheim | 8 | $122 |
| Shockwave Medical, Inc | 3 | $95 |
| E.r. Squibb & Sons, L.L.C. | 6 | $93 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $60 |
| Merck | 4 | $58 |
| Amarin Pharma, Inc. | 3 | $51 |
| Acist Medical Systems, Inc. | 1 | $43 |
| Gilead | 3 | $39 |
| Scpharmaceuticals Inc. | 2 | $38 |
| Angiodynamics, Inc. | 1 | $37 |
| Pfizer | 2 | $35 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $31 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $30 |
| Esperion Therapeutics, Inc. | 2 | $29 |
| Cardiva Medical, Inc. | 1 | $28 |
| Sanofi | 1 | $26 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Bayer | 1 | $20 |
| Altathera Pharmaceuticals LLC | 1 | $20 |
| Zimmer Biomet | 1 | $20 |
| Impulse Dynamics (USA) Inc. | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Philips North America LLC | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
| AstraZeneca | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,648 in reported general payments places this provider in the 50th percentile of 50 interventional cardiology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 508 | $459,595 |
| EntrestoSacubitril/Valsartan | 203 | $192,540 |
| Repatha SureclickEvolocumab | 135 | $120,235 |
| XareltoRivaroxaban | 43 | $59,609 |
| JardianceEmpagliflozin | 33 | $41,318 |
| BrilintaTicagrelor | 59 | $37,461 |
| Praluent PenAlirocumab | 39 | $23,066 |
| Ranolazine ErRanolazine | 110 | $15,032 |
| Metoprolol Succinate | 795 | $9,577 |
| FarxigaDapagliflozin Propanediol | 11 | $6,299 |
| Atorvastatin Calcium | 482 | $4,733 |
| Amiodarone Hcl | 169 | $4,496 |
| ClopidogrelClopidogrel Bisulfate | 375 | $3,340 |
| Carvedilol | 345 | $2,936 |
| Flecainide Acetate | 68 | $2,678 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $35 | $459,595508 claims |
| NovartisEntresto | $861 | $192,540203 claims |
| Johnson & JohnsonXarelto | $165 | $59,60943 claims |
| AstraZenecaBrilinta, Farxiga | $11 | $43,76070 claims |
| Boehringer IngelheimJardiance, Pradaxa | $122 | $43,65745 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 50 interventional cardiology providers in Nebraska.
Other interventional cardiology in Omaha
- Himanshu AgarwalOmaha$541K
- Poonam VelagapudiOmaha$142K
- Andrew GoldsweigOmaha$49K
- Jai ParekhOmaha$44K
- Scott CarolloOmaha$19K
- Shahbaz MalikOmaha$17K
- Toufik HaddadOmaha$14K
- Charles OlsonOmaha$12K
- Haysam AkkadOmaha$11K
- Ajaypaul SukhiOmaha$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.